Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV)
Jittamala P. et al, (2025), eClinicalMedicine, 80, 103036 - 103036
Evidence that remdesivir treatment reduces viral titers in patients with COVID-19.
Boyd S. et al, (2024), Antimicrobial agents and chemotherapy, 68
Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial
Schilling WHK. et al, (2024), PLOS Medicine, 21, e1004428 - e1004428
Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV)
Wongnak P. et al, (2024), The Lancet Infectious Diseases, 24, 953 - 963
Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial
Luvira V. et al, (2024), BMC Infectious Diseases, 24
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial
Schilling WHK. et al, (2024), The Lancet Infectious Diseases, 24, 36 - 45
Reflections on Participation in a Trial on Hydroxychloroquine as Prevention for COVID-19 among Health Workers in Niger.
Kabore Y. et al, (2023), The American journal of tropical medicine and hygiene, 109, 511 - 514
Antimicrobial resistance patterns in bacteria causing febrile illness in Africa, South Asia, and Southeast Asia: a systematic review of published etiological studies from 1980-2015
Roberts T. et al, (2022), International Journal of Infectious Diseases, 122, 612 - 621
Defining the burden of febrile illness in rural South and Southeast Asia: an open letter to announce the launch of the Rural Febrile Illness project
Chandna A. et al, (2022), Wellcome Open Research, 6, 64 - 64
Defining the burden of febrile illness in rural South and Southeast Asia: an open letter to announce the launch of the Rural Febrile Illness project
Chandna A. et al, (2022), Wellcome Open Research, 6, 64 - 64
Improving empiric antibiotic prescribing in pediatric bloodstream infections: a potential application of weighted-incidence syndromic combination antibiograms (WISCA)
Cook A. et al, (2022), Expert Review of Anti-infective Therapy, 20, 445 - 456
The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions
Schilling WHK. et al, (2021), Wellcome Open Research, 6, 71 - 71
Good participatory practice for coronavirus disease 2019 (COVID-19) research: the case of a COVID-19 prevention study
Perrone C. et al, (2021), Wellcome Open Research, 6, 216 - 216
Does hydroxychloroquine still have any role in the COVID-19 pandemic?
Schilling WH. and White NJ., (2021), Expert opinion on pharmacotherapy, 22, 1257 - 1266
The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions
Schilling WHK. et al, (2021), Wellcome Open Research, 6, 71 - 71
Defining the burden of febrile illness in rural South and Southeast Asia: an open letter to announce the launch of the Rural Febrile Illness project
Chandna A. et al, (2021), Wellcome Open Research, 6, 64 - 64
Good participatory practice for coronavirus disease 2019 (COVID-19) research: the case of a COVID-19 prevention study.
Perrone C. et al, (2021), Wellcome open research, 6
The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions.
Schilling WH. et al, (2021), Wellcome open research, 6
No evidence that chloroquine or hydroxychloroquine induce hemolysis in G6PD deficiency
Schilling WHK. et al, (2020), Blood Cells, Molecules, and Diseases, 85, 102484 - 102484
Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; protocol for a randomised, placebo-controlled prophylaxis study (COPCOV)
Schilling WHK. et al, (2020), Wellcome Open Research, 5, 241 - 241